

## Supplementary Online Content

Dewland TA, Soliman EZ, Davis BR, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT Collaborative Research Group. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on conduction system disease: a secondary analysis of a randomized clinical trial. *JAMA Intern Med*. Published online June 27, 2016.  
doi:10.1001/jamainternmed.2016.2502.

**eTable 1.** ALLHAT Comorbidity Definitions

**eTable 2.** Criteria for Conduction System Disease Diagnosis

**eTable 3.** Baseline Characteristics of ALLHAT Participants With and Without Serial Electrocardiograms

**eTable 4.** Antihypertensive Randomization and Blood Pressure

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1. ALLHAT Comorbidity Definitions**

| <b>Comorbidity</b>     | <b>Definition</b>  |
|------------------------|--|
| Coronary Heart Disease | History of myocardial infarction, angina, primary cardiac arrest, coronary stenosis > 50%, reversible perfusion defect on stress testing, or prior coronary revascularization procedure. |
| Diabetes               | Fasting plasma glucose > 140 mg/dl, a non-fasting glucose > 200 mg/dl, or treatment with insulin or oral hypoglycemic agent during the two years prior to study enrollment               |
| Smoking Status         |  |
| Current Smoker         | Any cigarette use within 30 days of enrollment   |
| Non Smoker             | No cigarette use within 30 days of enrollment  |

**eTable 2. Criteria for Conduction System Disease Diagnosis**

| Conduction Disease Diagnosis         | Minnesota Code | Definition   |
|--------------------------------------|----------------|--|
| First Degree AV Block                | 6-3            | PR interval $\geq$ 220 ms  |
| Left Anterior Fascicular Block       | 7-7            | QRS duration $<$ 120 ms, plus Q-wave amplitude $\geq$ 0.25 mm and $<$ 30 ms duration in lead I, plus left axis deviation of -45 degrees or more                        |
| Incomplete Left Bundle Branch Block  | 7-6            | QRS duration $\geq$ 110 ms and $<$ 120 ms without Q waves in I, aVL, V5, or V6   |
| Left Bundle Branch Block             | 7-1-1          | QRS duration $\geq$ 120 ms with an R peak duration $\geq$ 60 ms in leads I, II, aVL, V5, or V6   |
| Incomplete Right Bundle Branch Block | 7-3            | QRS duration $\leq$ 120 ms and R' $>$ R in either leads V1 or V2   |
| Right Bundle Branch Block            | 7-2-1          | QRS duration $\geq$ 120 ms, a R' $>$ R or mainly upright QRS in V1, and either a R peak duration $\geq$ 60 ms in V1/V2 or a S duration $>$ R duration in leads I or II |
| Intraventricular conduction delay    | 7-4            | QRS duration $\geq$ 120 ms not fulfilling either LBBB or RBBB criteria   |

LBBB, left bundle branch block; ms, milliseconds; RBBB, right bundle branch block.

**eTable 3. Baseline Characteristics of ALLHAT Participants With and Without Serial Electrocardiograms**

|  | <b>ECG Present<br/>(n = 21,004)</b> | <b>ECG Absent*<br/>(n = 10,691)</b> | <b>P value<sup>†</sup></b> |
|--|-------------------------------------|-------------------------------------|----------------------------|
| Age, years, mean (SD)                          | 66.5 (7.3)                          | 67.2 (8.3)                          | <0.001                     |
| Female Gender, n (%)                           | 9,322 (44.4)                        | 5,776 (54.0)                        | <0.001                     |
| Race / Ethnicity, n (%)                        |                                     |                                     | <0.001                     |
| White Non-Hispanic                             | 11,093 (52.8)                       | 3,664 (34.3)                        |                            |
| White Hispanic                                 | 2,747 (13.1)                        | 2,304 (21.6)                        |                            |
| Black  | 6,805 (32.4)                        | 4,555 (42.6)                        |                            |
| Other <sup>‡</sup>                             | 359 (1.7)                           | 168 (1.6)                           |                            |
| Body Mass Index, kg/m <sup>2</sup> , mean (SD) | 29.8 (6.0)                          | 29.7 (6.5)                          | 0.47                       |
| Current Smoker, n (%)                          | 4,528 (21.6)                        | 2,511 (23.5)                        | <0.001                     |
| Prior Antihypertensive Treatment, n (%)        | 19,015 (90.5)                       | 9,542 (89.3)                        | <0.001                     |
| Aspirin Use, n (%)                             | 8,012 (38.5)                        | 3,174 (30.3)                        | <0.001                     |
| Diabetes, n (%)                                | 7,848 (39.7)                        | 4,668 (48.3)                        | <0.001                     |
| Coronary Heart Disease, n (%)                  | 5,296 (25.4)                        | 2,505 (23.6)                        | <0.001                     |
| Left Ventricular Hypertrophy, n (%)            | 1,235 (5.9)                         | 532 (9.4)                           | <0.001                     |
| GFR, ml/min/1.73 m <sup>2</sup> , mean (SD)    | 77.93 (18.8)                        | 77.8 (21.6)                         | 0.56                       |
| Serum potassium, mEq/L, mean (SD)              | 4.30 (0.5)                          | 4.32 (0.5)                          | 0.020                      |
| Cholesterol, mg/dL, mean (SD)                  |                                     |                                     |                            |
| Total  | 215.8 (42.4)                        | 217.8 (45.6)                        | <0.001                     |
| HDL  | 46.5 (14.7)                         | 48.0 (15.0)                         | <0.001                     |
| LDL  | 135.8 (36.4)                        | 136.5 (38.7)                        | 0.14                       |
| Antihypertensive treatment group, n (%)        |                                     |                                     | <0.001                     |
| Chlorthalidone                                 | 9,726 (46.3)                        | 4,757 (44.5)                        |                            |
| Amlodipine                                     | 5,736 (27.3)                        | 2,868 (26.8)                        |                            |

|                              |              |              |       |
|------------------------------|--------------|--------------|-------|
| Lisinopril                   | 5,542 (26.4) | 3,066 (28.7) |       |
| Pravastatin treatment, n (%) | 2,882 (13.7) | 992 (9.3)    | 0.547 |

\*Participants without a baseline and at least one follow-up ECG are labeled as “ECG absent” and were excluded from the incident analysis. †P values are for the comparison of the indicated characteristic among participants with and without serial ECGs.

‡Participants who did not identify as White, Black, or Hispanic were included in the “Other” race category. Individuals with missing data were omitted from the proportion calculations for the missing variable. CI, confidence interval; ECG, electrocardiogram; GFR, glomerular filtration rate; HDL, high density lipoprotein, HTN, hypertension; HR, hazard ratio; LDL, low density lipoprotein; SD, standard deviation.

**eTable 4. Antihypertensive Randomization and Blood Pressure**

|   | <b>Chlorthalidone</b> | <b>Amlodipine</b> | <b>Lisinopril</b> | <b>P value*</b> | <b>P value†</b> | <b>P value‡</b> |
|---|-----------------------|-------------------|-------------------|-----------------|-----------------|-----------------|
| <b>Systolic Blood Pressure, mean (SD), mm Hg</b>  |                       |                   |                   |                 |                 |                 |
| Baseline  | 145.8 (15.7)          | 145.8 (15.8)      | 145.7 (15.4)      | 0.83            | 0.84            | 0.71            |
| 1 Year  | 136.3 (15.2)          | 138.0 (14.4)      | 139.3 (18.1)      | <0.001          | <0.001          | <0.001          |
| 2 Years   | 135.4 (15.5)          | 136.6 (14.4)      | 138.1 (17.6)      | <0.001          | <0.001          | <0.001          |
| 3 Years   | 134.4 (14.9)          | 135.0 (14.6)      | 136.2 (17.1)      | 0.01            | <0.001          | <0.001          |
| 4 Years   | 134.0 (15.4)          | 134.8 (15.1)      | 135.5 (17.0)      | 0.01            | <0.001          | 0.09            |
| 5 Years   | 133.9 (14.9)          | 134.9 (14.4)      | 136.1 (17.9)      | 0.02            | <0.001          | 0.02            |
| <b>Diastolic Blood Pressure, mean (SD), mm Hg</b> |                       |                   |                   |                 |                 |                 |
| Baseline  | 84.0 (10.0)           | 83.9 (10.1)       | 84.0 (9.9)        | 0.47            | 0.97            | 0.50            |
| 1 Year  | 79.3 (9.2)            | 78.5 (9.3)        | 79.6 (10.2)       | <0.001          | 0.05            | <0.001          |
| 2 Years   | 78.3 (9.5)            | 77.4 (9.4)        | 78.5 (10.1)       | <0.001          | 0.18            | <0.001          |
| 3 Years   | 77.1 (9.3)            | 76.1 (9.3)        | 77.0 (10.2)       | <0.001          | 0.70            | <0.001          |
| 4 Years   | 76.5 (9.6)            | 75.7 (9.6)        | 76.5 (10.3)       | <0.001          | 0.99            | <0.001          |
| 5 Years   | 75.5 (9.7)            | 74.5 (9.7)        | 75.4 (10.4)       | <0.001          | 0.86            | 0.003           |

\*P value for comparison of amlodipine versus chlorthalidone. †P value for comparison of lisinopril versus chlorthalidone. ‡P value for comparison of amlodipine versus lisinopril. SD, standard deviation.